A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-072 After Discontinuation of ABT-072 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-072 Clinical Studies
A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-072 After Discontinuation of ABT-072 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-072 Clinical Studies
This is a follow-up study with no treatment and only samples being collected.
The purpose of this study is to evaluate the development of specific viral mutations in response to treatment with ABT-072.
Inclusion Criteria:
- Main Selection Criteria: A subject that has received either ABT-072 or placebo in a prior study involving ABT-072.
Exclusion Criteria:
- The investigator considers the subject unsuitable for the study for any reasons inclusive of, but not limited to, failure to comply with study procedures in a prior ABT-072 clinical study.